Pathos AI
IL - ChicagoBiotechnology
Focus: Pathos AI is an early-stage oncology biotech focused on in-licensing clinical-stage drugs, with a Series A funding model and lean headcount. The company operates from Chicago and is building a portfolio around precision oncology assets.
Profile data last refreshed 4h ago · AI intelligence enriched 2mo ago
Funding Stage
SERIES A
Open Jobs
3-2 this month
Stable — net -2 jobs in 30d
0 added, 2 removed. Backfill posture.
Should You Work at Pathos AI?
AI assessmentPathos AI offers early-stage oncology upside and hands-on ownership for risk-tolerant pharma professionals, but financial runway and pipeline depth remain unproven.
Why Work Here
- Ground-floor opportunity at a Series A oncology in-licenser with recent strategic acquisition of DeuterOncology (May 2026), signaling growth intent and asset strategy.
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
PHASE_1_2
Clinical Trials (1)
NCT06785636A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
Phase 1/2Help build intelligence for Pathos AI
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.